Mutual of America Capital Management LLC Sells 2,069 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Mutual of America Capital Management LLC reduced its stake in Vertex Pharmaceuticals by 6.6%, selling 2,069 shares, and now holds 29,406 shares valued at approximately $13.1 million.
• Vertex Pharmaceuticals received mixed ratings from analysts, with one upgrading the stock to "strong-buy" while others decreased their price targets, leading to an average rating of "Moderate Buy" and a target of $494.38.
• Earlier this quarter, Vertex Pharmaceuticals reported a **net margin of 31.86%** and a P/E ratio of 29.79, indicating strong financial performance with an EPS of $4.52, surpassing analyst expectations.

Mutual of America Capital Management LLC lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 6.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,406 shares of the pharmaceutical company's stock after selling 2,069 shares during the quarter. Mutual of America Capital Management LLC's holdings in Vertex Pharmaceuticals were worth $13,092,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Activest Wealth Management bought a new stake in Vertex Pharmaceuticals in the first quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 45 shares during the period. Flaharty Asset Management LLC bought a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $32,000. American National Bank & Trust boosted its holdings in Vertex Pharmaceuticals by 515.4% during the 2nd quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company's stock valued at $36,000 after acquiring an additional 67 shares during the period. Finally, University of Texas Texas AM Investment Management Co. bought a new position in Vertex Pharmaceuticals in the 1st quarter valued at $46,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several research analyst reports. Scotiabank decreased their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a "sector perform" rating for the company in a research report on Tuesday, August 5th. Morgan Stanley decreased their price objective on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an "equal weight" rating for the company in a report on Friday, October 10th. Leerink Partnrs raised shares of Vertex Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, September 25th. Leerink Partners raised shares of Vertex Pharmaceuticals from a "market perform" rating to an "outperform" rating and reduced their target price for the stock from $458.00 to $456.00 in a research report on Thursday, September 25th. Finally, Royal Bank Of Canada decreased their price target on shares of Vertex Pharmaceuticals from $430.00 to $405.00 and set a "sector perform" rating for the company in a research note on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $494.38.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs acquired 5,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The shares were bought at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the transaction, the director directly owned 45,000 shares in the company, valued at $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $416.81 on Friday. The firm has a 50-day simple moving average of $395.46 and a 200-day simple moving average of $436.43. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.88. The firm has a market cap of $106.87 billion, a P/E ratio of 29.79 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. The company had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. Vertex Pharmaceuticals's revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.